Analysis of the Ukrainian market of parapharmaceuticals for prevention of keloid scars

• Main Authors: Alla Nemchenko, Vikotria Nazarkina, Viktoria Mishchenko, Elena Vinnik
• Format: Article
• Language: English
• Published: PC Technology Center 2018-04-01
• Series: ScienceRise: Pharmaceutical Science
• Subjects: келоїди; парафармацевтика; аналіз парафармацевтичного ринку; профілактика утворення келоїдів; цінова доступність парафармацевтиків
• Online Access: http://journals.uran.ua/sr_pharm/article/view/128867
• ISSN: 2519-4844; 2519-4852

An analysis of the anti-keloid parapharmaceuticals (AKPF) market, for preventing the formation of keloid scar (KS) and providing the population with affordable drugs is an urgent issue at this time. Doctors have not yet identified the reasons for the formation of KS. The tendency to keloid formation was noted in such cases as: after surgical interventions, heredity, ethnic factors, immune pathologies, etc. Aim of the research was to analyze the Ukrainian market of parapharmaceuticals (PF), which are used to prevent the formation of keloids. Materials and methods. Materials of the study were selected assortment of AKPF for the treatment of CS, which is present on the domestic market during 2015-2017 by statistical, analytical and economic-mathematical methods of analysis. Results of the research show that PFs are used in prophylactic, physiotherapeutic, pharmacotherapeutic and pharmaceutical methods of treatment of KS and cosmetology procedures. The Ukrainian market of AKPF is represented exclusively by domestic producers (“Euro plus”, PP “Ekobiz”, TOV NVO "PhytoBiotechnology", a group of companies "Elfa", etc.). The suad of PF most often includes heparin, onion extract, D-panthenol. The presence of funds of the same composition is noted, but some are in market as drug and others - as PF. For consumers in the annotations on AKPF it is advisable to clearly recommend them to use PH only for the purpose of the first pre-care and prevention of the formation of keloids. Conclusions indicate that the highest proportion of AKPF (42.9 %) is presented in the form of a gel. In the analysis of AKPF price indexes for 2015–2017, it was established that the indicator of the liquidity ratio is within the range of 0.133–0.433. All domestic AKPFs have a high coefficient of solvency adequacy in 2015–2017. For 2015-2016, all calculated values of the availability of the analyzed goods are equal to or greater than one (D ≥ 1). But in 2017 the value of the analyzed indicator is less than one, which is the result of an unstable situation in the pharmaceutical market of the country